Add Row 
Add 
A Revolutionary Approach to Drug Discovery
Utrecht-based Laigo Bio has recently completed an impressive €17 million seed funding round, co-led by Biovance Capital and Kurma Partners. This funding will accelerate the development of Laigo's innovative SureTACs platform, which targets difficult membrane proteins associated with cancer and autoimmune diseases. Unlike conventional drugs that block protein functions, SureTACs aim to physically eliminate these problematic proteins by harnessing the cell’s internal machinery for degradation.
What are SureTACs and Why are They Important?
SureTACs, short for Surface Removal Targeting Chimeras, employ a unique mechanism: by creating bispecific antibodies that facilitate the degradation of disease-causing membrane proteins through proximity to E3 ligase enzymes. This method effectively puts the targeted proteins in a position where they trigger the cell's own degradation pathways, thereby achieving a more selective removal of harmful proteins compared to traditional methods that merely inhibit them.
Investment and Future Goals
The latest funding marks a significant leap for Laigo Bio, adding to the €11.5 million raised late last year. With this new capital, the company aims to further its oncology programs through critical preclinical studies. Additionally, Laigo plans to explore three other therapeutic areas that focus on autoimmune diseases and conditions like graft rejection. As more pharmaceutical partners are anticipated to join as the projects progress, the potential for transformative therapies continues to grow.
Laigo's Unique Position in the Biotech Landscape
Laigo Bio stands out not just for its innovative approach but also for the rich backing it has received from established investors, including Argobio Studio and Cancer Research Horizons. The unique aspect of their technology is that it not only focuses on the traditional aspects of drug development but also tackles membrane proteins, which have been largely considered undruggable until now. This opens a significant window of opportunity for discovering new treatments.
The Impact of Targeting Undruggable Proteins
Historically, many diseases have been challenging to treat due to a lack of effective targets in drug development. The success of Laigo Bio signals a potential shift in this narrative, allowing for the targeting of previously elusive proteins in cancer and autoimmune conditions. This could lead to breakthrough therapies that not only improve survival rates but also reduce side effects commonly associated with existing treatments.
Write A Comment